RE: Added21 Oct 2020 11:26
Similarly, I added at higher prices. The reaction to a £40M contract seems rather irrational, but that's the short-term market for ya. The fundamentals and pipeline look wonderful, so I see no rational reason for it; the SP did not appear to be unreasonable given what's already known, and what's upcoming.
Like you, I'm confident for the mid-to-long term. Heck, just as likely to see it turn around in the short term with how crazy AIM has been lately.
Likely news-flow include potentially massive wearables deal, Imutex spinoff/sale, further covid and non-covid challenge study signups, additional challenge study facilities coming online, further deals for testing/validation, etc.